PureTech Health PLC

NASDAQ PRTC

Data sourced from

and

Download Data

PureTech Health PLC Gross Working Capital for the year ending December 31, 2023: USD 288.57 M

PureTech Health PLC Gross Working Capital is USD 288.57 M for the year ending December 31, 2023, a 4.24% change year over year. Gross working capital is a financial metric that represents the amount of a company's current assets available to cover its current liabilities and short-term debt obligations. It is calculated by subtracting the sum of current liabilities and short-term debt from the total current assets of a company. Gross working capital provides insights into a company's short-term liquidity and its ability to meet its financial obligations in the near future.

PureTech Health PLC Gross Working Capital for the year ending December 31, 2022 was USD 276.83 M, a 3.70% change year over year.
PureTech Health PLC Gross Working Capital for the year ending December 31, 2021 was USD 266.95 M, a 31.05% change year over year.
PureTech Health PLC Gross Working Capital for the year ending December 31, 2020 was USD 203.71 M, a 706.44% change year over year.
PureTech Health PLC Gross Working Capital for the year ending December 31, 2019 was USD 25.26 M, a 240.43% change year over year.

NASDAQ: PRTC

PureTech Health PLC

CEO	Ms. Daphne Zohar
IPO Date	Nov. 16, 2020
Location	United States
Headquarters	6 Tide Street, Boston, MA, United States, 02210
Employees	90
Sector	Healthcare
Industry	Biotechnology

Description

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Key trends